摘要
目的观察分析GP全身化疗联合吡柔比星热灌注治疗晚期膀胱癌的临床疗效及不良反应。方法方便选取2015年4月—2016年4月在赤峰市第二医院收治的64例晚期膀胱癌患者作为观察对象,并随机分为观察组(32例)和对照组(32例),对照组患者给予吉西他滨+顺铂(GP)方法进行全身化疗,观察组患者在对照组基础上联合吡柔比星热灌注化疗,比较两组患者的临床疗效及不良反应发生率。结果观察组临床有效率(75.00%)及不良反应情况明显优于对照组(46.88%)(P<0.05)。结论 GP全身化疗联合吡柔比星热灌注对治疗晚期膀胱癌患者的临床疗效有明显的改善,提高了患者的生活质量,并未见及未增加明显相关的不良反应,故值得认可和推广。
Objective To observe and analyze the clinical curative effect and adverse reactions of GP general chemotherapy and pirarubicin hyperthermal perfusion therapy for advanced bladder cancer. Methods 64 cases of patients with advanced bladder cancer admitted and treated in our hospital from April 2015 to April 2016 were convenient selected and randomly divided into two groups with 32 cases in each, the control group adopted the gemcitabine and GP general chemotherapy,while the observation group adopted the pirarubicin hyperthermal perfusion therapy on the basis of the control group, and the clinical curative effect and incidence rate of adverse reactions were compared between the two groups. Results The clinical effective rate and adverse reactions in the observation group were better than those in the control group(75.00% vs46.88%)(P<0.05). Conclusion The clinical curative effect of GP general chemotherapy and pirarubicin hyperthermal perfusion therapy for advanced bladder cancer is obviously improved, which improves the quality of life of patients without obvious adverse reactions, and it is worth recognition and promotion.
出处
《中外医疗》
2017年第20期110-112,共3页
China & Foreign Medical Treatment
关键词
全身化疗
吡柔比星
晚期膀胱癌
临床疗效
不良反应
General chemotherapy
Pirarubicin
Advanced bladder cancer
Clinical curative effect
Adverse reactions
